Entact Bio CEO Victoria Richon

En­tact Bio makes its Se­ries A de­but with $81M to launch pro­tein en­hance­ment plat­form

En­tact Bio has se­cured $81 mil­lion in a Se­ries A round to push for­ward its plat­form for de­vel­op­ing ther­a­pies that can en­hance the func­tion of pro­teins that are cru­cial to fight dis­ease.

Known as en­hance­ment-tar­get­ing chimeric (EN­TAC) mol­e­cules, En­tact’s idea is to use the drug plat­form in the treat­ment of cer­tain can­cers, in­flam­ma­to­ry dis­eases and rare ge­net­ic dis­or­ders as­so­ci­at­ed with hap­loin­suf­fi­ciences, in which pa­tients have too lit­tle of a pro­tein in their cells. Be­cause EN­TACs are small mol­e­cules, they can be oral­ly de­liv­ered and are much cheap­er to man­u­fac­ture.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.